Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/60805 |
Resumo: | Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations”. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed. |
id |
RCAP_626ed20073fffd06a089ae1a8140a1cd |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/60805 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signalinglung cancerEGFRRKIP signalingprognosiscancer therapyScience & TechnologyLung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations”. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed.This research was partially funded by the projects NORTE-01-0145-FEDER-000013 and NORTE-010145-FEDER-000023, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). The D.C.-C. was funded by a PhD fellowship (SFRH/BD/141200/2018) from Fundação para a Ciência e Tecnologia (FCT), Portugal and O.M. was funded by a post-doc fellowship (SFRH/BPD/108351/2015) from FCT, Portugal.info:eu-repo/semantics/publishedVersionMultidisciplinary Digital Publishing InstituteUniversidade do MinhoRaquel-Cunha, AnaCardoso-Carneiro, DianaReis, R. M.Martinho, Olga2019-05-102019-05-10T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/60805eng2073-440910.3390/cells8050442info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:22:27Zoai:repositorium.sdum.uminho.pt:1822/60805Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:15:56.221915Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
title |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
spellingShingle |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling Raquel-Cunha, Ana lung cancer EGFR RKIP signaling prognosis cancer therapy Science & Technology |
title_short |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
title_full |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
title_fullStr |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
title_full_unstemmed |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
title_sort |
Current status of Raf Kinase Inhibitor Protein (RKIP) in lung cancer: behind RTK signaling |
author |
Raquel-Cunha, Ana |
author_facet |
Raquel-Cunha, Ana Cardoso-Carneiro, Diana Reis, R. M. Martinho, Olga |
author_role |
author |
author2 |
Cardoso-Carneiro, Diana Reis, R. M. Martinho, Olga |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Raquel-Cunha, Ana Cardoso-Carneiro, Diana Reis, R. M. Martinho, Olga |
dc.subject.por.fl_str_mv |
lung cancer EGFR RKIP signaling prognosis cancer therapy Science & Technology |
topic |
lung cancer EGFR RKIP signaling prognosis cancer therapy Science & Technology |
description |
Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations”. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-10 2019-05-10T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/60805 |
url |
http://hdl.handle.net/1822/60805 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2073-4409 10.3390/cells8050442 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132606527176704 |